Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer
作者机构：Duke University Medical Center Durham NC United States Kansai Medical University Shinmachi Hirakata Japan University of Florida Gainesville United States Memorial Sloan Kettering Cancer Center New York United States Gustave Roussy Cancer Center Université Paris-Saclay Villejuif France Huntsman Cancer Institute University of Utah Salt Lake City United States West German Cancer Center University Hospital Essen Essen Germany University of Pittsburgh Medical Center Hillman Cancer Center Pittsburgh United States Fred Hutchinson Cancer Center University of Washington Seattle United States Sarah Cannon Research Institute at HealthONE Denver United States London Regional Cancer Program London ON Canada St. Marianna University School of Medicine Kawasaki Japan Marseille University Hospital Marseille France University Hospitals Cleveland Medical Center Cleveland United States Yonsei Cancer Center Seoul South Korea Scientia Clinical Research and Prince of Wales Clinical School University of New South Wales Sydney Australia Massachusetts General Cancer Center Boston United States Amgen Thousand Oaks CA United States University of Texas M.D. Anderson Cancer Center Houston United States
出 版 物：《四川生理科学杂志》 (Sichuan Journal of Physiological Sciences)
年 卷 期：2022年第44卷第12期
页 面：2100-2100页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy
摘 要：Background:KRAS p.G12C mutation occurs in approximately 1 to 2%of pancreatic *** safety and efficacy of sotorasib,a KRAS G12C inhibitor,in previously treated patients with KRAS p.G12C-mutated pancreatic cancer are ***:We conducted a single-group,phase 1-2 trial to assess the safety and efficacy of sotorasib treatment in patients with KRAS p.G12C-mutated pancreatic cancer who had received at least one previous systemic therapy.
维普期刊数据库